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P. S. COLEMAN, M. S. PARMACEK, M. LESCH AND A. M. SAMAREL. Protein Synthesis and Degradation During 
Regression of Thyroxine-induced Cardiac Hypertrophy. Journal of Molecular and Cellular Cardiol (1989) 21, 
91 l-925. To characterize changes in rates of protein turnover during regression of thyroxine-induced left 
ventricular hypertrophy, New Zealand White rabbits received intravenous thyroxine (200 pg/kg/d) for 9 days. 
Thyroxine was withheld, and in uiuo protein turnover was evaluated on the IOth, 15th and 20th days. Animals 
not receiving thyroxine served as controls. Heart rate, blood pressure, and rate-pressure product were measured 
to correlate changes in cardiac work with protein turnover rates during the development and regression of 
hypertrophy. Thyroxine administration produced left ventricular hypertrophy by increasing the rate of protein 
synthesis (from 37.9 + 8.9 to 64.1 f 15.3 mg/day; P < 0.05) to a greater degree than protein degradation (from 
29.8 + 8.9 to 48.2 f 15.3 mg/day for control and thyroxine-treated animals, respectively; P < 0.05). Cessation 
of thyroxine administration resulted in an eventual return of left ventricular mass to that of normally growing 
control animals. The major observation noted during thyroxine withdrawal was a return of protein synthetic 
rates to normal. Absolute rates ofprotein degradation remained elevated, whereas fractional protein degradative 
rates (i.e. the fraction of total protein degraded per day) were unchanged by the administration and withdrawal 
of thyroxine. These results indicate that suppression of both physiological and hormone-induced growth 
following cessation of thyroxine resulted from a decrease in cardiac protein synthetic rates and an increased rate 
of flux through the protein degradative pathway(s), while fractional rates of protein degradation (and thus 
average protein half-life) remained unchanged. The development and regression of thyroxine-induced hyper- 
trophy correlated with thyroxine-mediated alterations in cardiac work. 
KEY WORDS: Thyroxine; Thyrotoxicosis; Heart Enlargement; Muscle Proteins; Kinetics; Cardiac Work; 
Proteolysis; Myofibril. 
Introduction 
Hypertrophy is an adaptive response of ven- 
tricular myocardium to a variety of physiolog- 
ical and pathological stimuli. Removal of the 
stimulus responsible for the growth process 
usually results in a return of cardiac mass to 
normal. For example, regression of cardiac 
hypertrophy following reversal of chronic left 
ventricular pressure overload has been de- 
monstrated in both experimental animals and 
man (Beznak et al., 1969; Pandis et al., 1984). 
Experimental models of chronic volume 
overload have been less extensively studied, 
but replacement of the aortic valve in humans 
with aortic insufficiency has often, but not 
always, been associated with a return of ven- 
tricular mass towards normal (Pandis et al., 
1984). The intracellular mechanisms respon- 
sible for the regression of myocardial hyper- 
trophy are poorly understood, but must ulti- 
mately depend upon changes in the opposing 
processes of cardiac protein synthesis and de- 
Abbreviations: TCP-total cardiac protein; DNA-deoxyribonucleic acid; RNA-ribonucleic acid; LV-left ventricle; 
RV-right ventricle; R,-absolute rate of protein synthesis; Rs-absolute rate of protein accumulation; Rd-absolute 
rate of protein degradation; K-fractional rate of protein synthesis; Ks-fractional rate of protein accumulation; Kh-- 
fractional rate of protein degradation. 
All correspondences should be sent to: Allen M. Samarel, Department of Medicine, Loyola University Medical 
Center, 21605 First Ave, Maywood, IL 60153, USA. 
0022-2828/89/090911 f 15 003.00/O 0 1989 Academic Press Limited 
912 P. S. Coleman et al. 
gradation. Alterations in the rates of one or 
both of these processes must explain the cess- 
ation of the growth process and the regression 
of myocardial protein mass. 
Thyroxine administration is a reproducible 
and extensively studied model for the develop- 
ment of cardiac hypertrophy. We have previ- 
ously shown that thyroxine-induced cardiac 
hypertrophy is associated with both increased 
fractional and absolute rates of in vivo protein 
synthesis, as well as increases in the efficiency 
and capacity for protein synthesis (Parmacek 
et al., 1986). Measurements of protein de- 
gradative rates in this hormone induced 
model of hypertrophy vary, but in all cases, 
hypertrophy occurs because the accelerated 
rate of new protein synthesis exceeds the rate 
of degradation (Morgan et al., 1987). 
Regression of thyroxine-induced cardiac 
hypertrophy has been less extensively studied. 
In isolated, perfused rat hearts studied 4 days 
after the cessation of thyroxine administra- 
tion, Sanford et al. (1978) demonstrated re- 
gression of myocardial mass that was as- 
sociated with a decrease in both the fractional 
rates of cardiac protein synthesis and degrad- 
ation. However, due to methodological dif- 
ficulties in assessing in vitro rates of protein 
degradation, direct comparisons of the rates of 
protein synthesis and degradation during re- 
gression could not be made. Therefore, these 
in vitro studies did not define to what extent 
each process contributes to the regression of 
cardiac hypertrophy in vivo following the cess- 
ation of thyroxine administration. 
The proximal stimulus responsible for ac- 
celerated protein synthesis in excess of degrad- 
ation during thyroxine administration re- 
mains unclear. Thyroxine interacts with nu- 
clear receptors to induce the synthesis of a 
variety of new cardiac proteins, including a- 
myosin heavy chain (Zak et al., 1982; Klein, 
1988; Everett et al., 1984; Gustafson et al., 
1986). In addition, thyroxine treatment alters 
peripheral hemodynamics, thus changing the 
loading conditions of the left ventricle. Recent 
evidence has emphasized the importance of 
cardiac work necessary for the development of 
hypertrophy during thyroxine administration 
(Klein et al., 1986; Korecky et al., 1987). In 
addition, cessation of thyroxine administra- 
tion may not result in the immediate reso- 
lution of the thyroxine-induced changes in 
ventricular loading. Thus, analysis of re- 
gression from thyroxine-induced cardiac 
hypertrophy requires that hemodynamic 
changes occurring after cessation of hormone 
administration be correlated with changes in 
ventricular mass and ultimately, changes in 
the rates of cardiac protein synthesis and 
degradation. 
The objectives of this study were to assess 
the in vivo rates of protein synthesis and de- 
gradation in juvenile rabbits following ad- 
ministration and cessation of thyroxine. Non- 
invasive hemodynamic parameters were 
measured in order to correlate measurements 
of ventricular mass and rates of protein turn- 
over with indices of cardiac work. Data are 
presented which indicate that suppression of 
both physiological and hormone-induced 
growth following cessation of thyroxine results 
from a decrease in the rate of left ventricular 
protein synthesis and an increased rate of flux 
through the protein degradative pathway(s), 
However, fractional rates of protein degrad- 
ation (and thus average protein half-life) re- 
main unchanged during regression. Further- 
more, observed changes in the rates of protein 
synthesis temporally correlate with the reso- 
lution of increased cardiac work which occurs 
following withdrawal of thyroxine. 
Methods 
I. Reagents 
L-[2,3,4,5-3H]leucine (110 Ci/mmol) was ob- 
tained from ICN Biomedics, Costa Mesa, CA, 
USA [N-methyl t4C]dansyl chloride ( 112 
mCi/mmol) was obtained from Research Pro- 
ducts International, Rolling Meadows, IL. L- 
thyroxine (Sigma Chemical Co., St. Louis, 
MO, USA) was dissolved in 140 rnM NaOH to 
achieve a final concentration of4 mg/ml at pH 
10.5. All other reagents were of the highest 
grade commercially available, and were ob- 
tained from Baxter S/P, McGaw Park, IL, 
and the Sigma Chemical Co., St Louis, MO, 
USA. 
II. Experimental animals 
Male New Zealand white rabbits (Lesser’s 
Rabbitry, Union Grove, WI) were used in all 
experiments. Animals were acclimated to the 
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Northwestern University animal facility for 
l-3 weeks and weight gain documented prior 
to randomization to control or thyroxine- 
treated groups. Body weights and physiolog- 
ical measurements were obtained daily during 
the acclimation period to establish baseline 
indices for normal, growing rabbits and to 
familiarize the animals with handling and 
measurement procedures. Animals weighing 
1.90 to 2.10 kg were randomly assigned to 
either the control (C-O) or thyroxine-treated 
groups (Fig. 1). Thyroxine-treated animals 
received daily intravenous injections of L- 
thyroxine (200 fig/kg) for 9 days. Hormone 
administration was then discontinued, and the 
animals were randomly assigned to regression 
groups (R-0, R-l, R-3, R-5, R-7 and R-IO). 
The R-0 group consisted of rabbits that had 
not received thyroxine for 24 h, and were 
considered to have undergone no regression 
from thyroxine-induced cardiac hypertrophy. 
In the remaining thyroxine-treated animals, 
cardiac hypertrophy was subsequently al- 
lowed to regress for 1, 3, 5, 7 and 10 days, 
respectively. Each group consisted of a mini- 
mum of four animals. Rabbits were housed 
and fed ad libitum, as previously described 
(Samarel et al., 1981). 
III. Physiological measurements 
Physiological parameters and animal weight 
were measured daily between 7:00 and 10:00 
am. Body temperature was obtained using a 
flexible rectal probe attached to a digital 
thermometer. Respiratory rate was obtained 
over a 15 s period. Heart rate was obtained 
using a 6 s rhythm strip generated from a 3- 
lead electrocardiogram. Systolic and diastolic 
blood pressures were obtained using a Grant- 
Rothschild capsule (Wilson et al., 1975) placed 
over the right central ear artery. The mean of 
3 determinations was recorded. Pulse pressure 
was calculated as the difference between sys- 
tolic and diastolic blood pressures. Rate- 
pressure product was calculated as the pro- 
duct of systolic blood pressure and heart rate. 
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FIGURE 1. Experimental protocol used to assess regression of thyroxine induced cardiac hypertrophy. All animals 
were acclimated prior to inclusion into this study. Animals weighing 1.90 to 2.10 kg were randomly assigned to either 
the baseline group of the present study (C-O) or thyroxine-treated groups. Thyroxine-treated animals received daily 
intravenous injections of L-thyroxine (200 pg/kg) for 9 days. Hormone administration was then discontinued, and the 
animals were randomly assigned to regression groups (R-O, R-l, R-3, R-5, R-7 and R-10). The R-0 group consisted 
of rabbits that had not received thyroxine for 24 h, and were considered to have undergone no regression from 
thyroxine-induced cardiac hypertrophy. In the remaining thyroxine-treated animals, cardiac hypertrophy was 
subsequently allowed to regress for 1, 3, 5, 7 and 10 days, respectively. Each group consisted of a minimum of four 
animals. Control and thyrotoxic animals are included to demonstrate the treatment of animals used to generate the 
growth curves in Figure 3. (From Parmacek et al., 1986) 
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administered after all physiological measure- 
ments had been completed. 
IV. [3HJLeucine infusion technique 
Left ventricular (LV) total cardiac protein 
(TCP) synthesis was measured in vivo in GO, 
R-O, R-5 and R-10 animals (8 rabbits from 
each group) by the [3H]leucine constant infu- 
sion method (Parmacek et al., 1986). All infu- 
sions were begun between 8:00 and 9:00 a.m. 
to control for diurnal variation in TCP syn- 
thetic rates. Lightly restrained rabbits re- 
ceived an intravenous injection of sodium 
heparin (1000 p/kg) followed by a continuous 
intravenous infusion of L-[2,3,4,5- 
[3H]leucine, 150 mM NaCI, 10 p/ml heparin, 
100 PM unlabeled leucine (final leucine spe- 
cific radioactivity = 3750 @/pmol) at a rate 
of 1.33 ml/h (500 @i/h) for 4 h into a 
catheterized marginal ear vein. Arterial blood 
samples (0.6-1.0 ml) were obtained from the 
contralateral ear at 0, 5, 10, 20, 30, 60, 120, 
180 and 240 min during the infusion. The 
volume of sampled blood was replaced with an 
equal volume of sterile isotonic saline. 
V. Plasma total andfree thyroxine measurements 
Total and free thyroxine concentrations were 
measured in the plasma of C-O, R-O, R-5, 
R-IO animals used for protein synthetic ex- 
periments. Prior to infusion of [3H]leucine, 
blood samples were obtained and the plasma 
was assayed using a commercially available, 
direct antibody RIA method (Amerlex-M, 
Amersham, Arlington Heights, IL, USA). 
VI. Determination of ventricular tissue composition 
All animals were killed by an intravenous 
injection of an overdose of sodium pentobar- 
bital. The heart was rapidly excised via a 
median sternotomy incision and placed into 
150 mM NaCl (4°C) to remove blood. The 
heart was blotted dry, trimmed of fat and 
major blood vessels, and weighed. After deter- 
mination of total heart weight, the atria and 
right ventricular free wall were excised. The 
LV, consisting of the left ventricular free wall 
and septum, and the right ventricle (RV), 
were weighed separately, frozen in liquid 
nitrogen and stored at -80°C. 
Approximately 1 g of LV tissue from each 
heart was finely minced and suspended in 19 
vol of 100 lll~ KCl, 250 PM potassium thiogly- 
colate, pH 6.8. The tissue was homogenized 
by four 15 s bursts in a Polytron PCU homo- 
genizer (Brinkman Instruments, Westbury, 
NY, USA). A portion of the LV tissue homo- 
genate was used for protein determination by 
the method of Lowry et al. (195 1). Additional 
portions were removed for RNA and DNA 
determination. Total RNA concentration was 
analyzed by the method of Munro and Fleck 
( 1966). DNA concentration was assessed using 
a minor modification of the method of Cesa- 
rone et al. ( 1979). Results were expressed both 
as mg of total RNA or DNA per gram LV wet 
weight, and as mg of total protein or RNA per 
mg of total DNA. 
VII. Determination of leucine specijic radioactivity 
in plasma and LV total protein fractions 
Leucine specific radioactivity in the plasma 
and in TCA-precipitable total cardiac protein 
(TCP) was determined as previously de- 
scribed (Parmacek et al., 1986). 
VIII. Calculation of LV total cardiac protein 
fractional synthetic rates 
The fractional synthetic rates (K,, %/day) of 
LV TCP were calculated for each animal 
using the formula described by Everett et al. 
(1979): 
P* 
I(,= F* (I-:-x") 
[ 
1 -- & 1 
x 100 
where P* is the leucine specific radioactivity 
in LV TCP (dpmlnmol), F is the leucine 
specific radioactivity in the plasma at the end 
of the infusion (dpm/nmol), and Xr is the first 
order rate constant (days-‘) describing the 
rate of rise of plasma leucine specific radioac- 
tivity to plateau (pm, values were determined 
for each infusion experiment by non-linear, 
non-weighted regression analysis, as previ- 
ously described (Parmacek et al., 1986). This 
method assumes that the. specific radioactivity 
of leucyl-tRNA (the immediate precursor for 
protein synthesis) rapidly and completely 
equilibrates with the plasma leucine specific 
radioactivity in all experimental groups. 
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IX. Calculation ofplasma Eeucinejux 
Plasma leucine flux, an estimate ofwhole body 
protein synthesis (Water-low and Stephen, 
1967; Garlick et al., 1975), was calculated for 
each infusion animal using the following 
formula: 
leucine flux @mol/h) = 
infusion rate (@i/h) &$&Ci/~mol) / 100 g 
body weight 
X. Determination of LV total cardiac protein 
accumulation rates 
Values of LV TCP accumulation rates (Rs) for 
control and thyrotoxic rabbits had been pub- 
lished in our previous studies of thyroxine- 
induced left ventricular hypertrophy (Par- 
macek et al., 1986; Samarel et al., 1987). LV 
TCP accumulation rates (Rs) in the regression 
animals of the present study were directly 
determined from measurements of LV TCP 
and heart weight. Mean LV TCP content was 
plotted vs. days of regression. Sequential fit- 
ting of the data to first, second and third 
degree polynomial equations was then perfor- 
med and the improvement in fit was assessed 
by the significance of the partial F-value for 
the parameter of highest degree. TCP R, was 
then calculated as the first derivative of the 
best fitting function describing LV TCP cont- 
ent vs. time and expressed as mg protein 
accumulated/day. 
Instantaneous fractional accumulation 
rates (K,, %/day) were obtained by dividing 
the TCP R, by the LV TCP content/lOO. 
XI. Determination of LVprotein turnover in 
control, thyrotoxic, and regression animals 
LV TCP synthetic rates (R,, mg protein 
synthesized/day) were calculated as the pro- 
duct of the fractional synthetic rate (X,, 
%/day) and the corresponding total cardiac 
protein pool size [(mg protein/g LV wet wt) 
x (g LV wet wt/lOO)] of each animal. 
LV TCP degradative rates were calculated 
indirectly as either the fractional rate of de- 
gradation or the absolute rate of degradation. 
The fractional degradative rate (&, %/day) 
was calculated as the difference between frac- 
tional synthetic rates (.& %/day) and frac- 
tional accumulation rates (Xs, %/day) for 
each animal. Kd estimated the fraction of the 
TCP pool degraded per day. The absolute 
rate of LV TCP degradation (Rd, mg protein 
degraded/day) was calculated as the differ- 
ence getween LV TCP synthetic rates (R,), mg 
protein/day) and LV TCP accumulation rates 
(RB, mg protein/day). TCP Rd estimated the 
flux through the protein degradative 
pathway(s), and was affected by alterations in 
both the TCP pool size and/or the fractional 
amount of the pool degraded per day (&) . 
The efficiency of cardiac protein synthesis 
was assessed in each animal used in leucine 
infusion experiments. Efficiency was cal- 
culated as TCP R, divided by the total RNA 
content and expressed as mg protein 
synthesized/day/mg total RNA (Millward et 
al., 1973). 
XII. Data analysis 
Unless otherwise stated, all results were ex- 
pressed as mean & S.D. Normality was demon- 
strated with the Wilks-Shapiro test and homo- 
geneity of variance was established with 
Levene’s test. One-way analysis of variance 
(ANOVA) followed by the Student-Newman- 
Keuls test were used for statistical comparison 
between multiple groups. Polynomial curve 
fitting and statistical analysis was performed 
using the PROPHET computer system (Divi- 
sion of Research Resources, NIH) . 
Results 
I. Cardiac growth during administration and 
withdraw1 of thyroxine 
Sixty-nine rabbits were used to assess myo- 
cardial growth and composition after admini- 
stration and withdrawal of thyroxine (Table 
1). Initial body weights for all animals were 
similar. Administration of thyroxine for 9 days 
(R-O animals) resulted in a 20% decrease in 
body weight as compared to C-O animals. By 
the fifth day after cessation of hormone ad- 
ministration, the thyroxine-induced weight 
loss had resolved, and the animals continued 
to gain weight through the 10th day following 
hormone withdrawal. Cardiac hypertrophy 
was evident after 9 days of thyroid hormone, 
as reflected by a 25% increase in total heart 
weight. Proportional increases in RV and LV 
weights were observed. Total heart weight 
remained relatively constant following with- 
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total heart weight to body weight ratio in- 
creased 56% as compared to C-O rabbits. By 
the fifth day following discontinuation of thy- 
roxine, the total heart weight to body ratio 
was significantly less than R-O and R-3 values 
and continued to decrease through day 10 of 
regression. Given the relative constant values 
for total heart weight, decreases in total heart 
weight to body weight ratios seen after cess- 
ation of thyroxine administration were largely 
the result of increases in body weight. 
II. Physiological changes associated with 
administration and withdrawal of thyroxine 
The results of physiological measurements 
made during the treatment protocol are de- 
picted in Figure 2. A significant increase in 
heart rate was observed during the course of 
thyroxine administration (260 + 22 vs. 
360 + 35 beats/min for CO and R-6 animals, 
respectively; P < 0.05). The mean heart rate 
remained significantly elevated in R-3 
(a) I Heart rate 400 
1 Cc ) Temperature 
(e) Pulse pressure ( f ) Rate pressure 
0 Thyroxine 200 @g/kg 








-IO 0 IO 20 
Days 
FIGURE 2. Changes in cardiac work during the development and regression of left ventricular cardiac hypertrophy 
were assessed by comparing various physiological parameters VS. time. Experimental animals were acclimated to 
housing and testing conditions for 1 week prior to receiving intravenous thyroxine (200 pg/kg/d) for 9 days. Thyroxine 
was stopped, and regression was allowed to occur for up to 10 days. Values are mean f S.E.M. for 8-20 observations at 
each time point. As is evident, heart rate (A), respiratory rate (B), temperature (C), systolic blood pressure (D), pulse 
pressure (E), and rate-pressure product (F) increased following administration of thyroxine. All parameters returned to 
control levels by the 3rd to 5th day following cessation of hormone administration. 
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animals (3 10 f  39 beats/min), but by the 5th 
day following cessation of hormone the mean 
heart rate was similar to C-O values. Other 
physiological parameters (respiratory rate, 
body temperature, systolic blood pressure, 
pulse pressure, and rate-pressure product) re- 
sponded similarly. Diastolic blood pressure 
was the only parameter studied which did not 
significantly change with thyroxine adminis- 
tration and withdrawal. These changes in 
physiological parameters directly or indirectly 
determine cardiac work (Morkin et al., 1983). 
Thus, the data in Figure 2 indicate that ad- 
ministration of thyroxine resulted in an in- 
crease in cardiac work that appeared to re- 
solve within 3 to 5 days following cessation of 
the hormone. 
III. [ 3 Hlleucine infusion experiments 
[3H]leucine infusions were performed on a 
subset of 32 rabbits. Each of the four groups of 
animals used in the infusion experiments con- 
sisted of 8 randomly selected rabbits from the 
GO, R-O, R-5, and R-10 groups. E,, and EC, 
were found to be similar in all groups (Table 
2). However, plasma leucine flux (an index of 
whole-body protein synthesis) was significant- 
ly elevated in R-O animals and returned to the 
rate observed in C-O animals within 5 days 
after hormone withdrawal (Table 2). These 
changes in plasma leucine flux paralleled 
changes in the indices of cardiac work as 
described above (Fig. 2). 
IV. Total andfree thyroxine levels following 
administration and withdrawal of thyroxine 
Following administration of thyroxine for 9 
days (R-O animals), plasma concentrations of 
both total and free thyroxine were signifi- 
cantly elevated compared to C-O animals 
(Table 3). Cessation of thyroxine administra- 
tion for 5 days resulted in a significant de- 
crease in total thyroxine concentration below 
that of controls. By the 10th day, plasma total 
thyroxine concentration had returned to con- 
trol values. In a similar fashion free thyroxine 
concentration fell by the 5th day after discont- 
inuing thyroxine but returned to control 
values by day 10; however, the transient de- 
crease in free thyroxine concentration was not 
statistically significant. 
V. Eflects of thyroxine administration and 
withdrawal on left ventricular tissue composition 
The cardiac growth seen during thyroxine 
administration was associated with an in- 
crease in the capacity for protein synthesis as 
assessed by the total tissue RNA concen- 
tration, expressed as mg/g LV wet weight 
(Table 4). Total tissue RNA concentration 
returned to the level observed in C-O animals 
TABLE 2. Plasma leucine specific radioactivity and leucine flux during regression 




F$ (dpm/nmol) 1632 f  422 1195 f  396 1262 f  330 1315 -t 236 
Kf (days) 281 f  140 257 If: 40 150 & 85 315 Ifr 229 
Plasma 35.9 -I 8.8 62.08 f  13.3* 45.0 + 11.1 36.8 + 6.2 
Leucine flux 
(wol/W 100 d 
Experimental animals were given intravenous thyroxine (200 pg/kg/d) for 9 days. Thyrox- 
ine was stopped and regression allowed to occur for 0, 5, and 10 days (R-O, R-5, and R-10, 
respectively). Animals not receiving thyroxine served as controls (C-O). F*,, and & are 
computer-derived values for the plasma leucine specific radioactivity at plateau, and the first- 
order rate constant, respectively. Values are means + S.D. for each group; n, number of 
experimental animals in each group. P values were obtained by ANOVA followed by Stndent- 
Newman-Keuls test comparing data from each group of experimental animals. Values are 
P > 0.05 unless otherwise noted. 
*P < 0.05 vs. cro. 
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(n = 8) (n = 8) 
43.3 * 10.4 90.4 + 41.3*f 16.7 + 5.3* 38.3 &- 9.2t 
15.3 +_ 4.6 85.9 + 52.7* 2.5 + 1.4 12.5 f 3.6 
Experimental animals were given intravenous thyroxine (200 fig/kg) for 9 days. Thyroxine was 
stopped and regression allowed to occur for 0,5, and 10 days (R-0, R-5, R-10, respectively). Animals 
not receiving thyroxine served as controls (GO). Values are means f S.D. for each group; n, number 
of experimental animals in each group. P values were obtained by ANOVA followed by Student- 
Newman-Kuels test comparing data from each group of animals. Values are P > 0.05 unless 
otherwise stated. 
*P < 0.05 "S GO. 
tP < 0.05 vs R-5. 
within 5 days following cessation of hormone 
administration. Total DNA concentration, ex- 
pressed as mg/g LV wet weight, did not 
change significantly during administration or 
withdrawal of thyroxine. Only minor changes 
in LV TCP concentration (mg/g LV wet 
weight) were observed during the treatment 
protocol. The total protein to DNA ratio did 
not change significantly following administra- 
tion and withdrawal of thyroxine. In a similar 
fashion, thyroxine administration and with- 
drawal did not significantly alter the total 
RNA to DNA ratio. 
VI. Rates of left ventricular protein accumulation 
and calculation offractional growth rates during 
administration and withdrawal of thyroxine 
As in our previous studies of non-steady state 
cardiac protein turnover, weighted regression 
analysis afforded a means of quantifying rates 
of LV TCP accumulation or loss (R8) during 
administration and withdrawal of thyroxine 
(Fig. 3). Weighted regression lines for LV 
TCP accumulation in control and thyrotoxic 
rabbits were obtained from our previous data 
(Parmacek et al., 1986; Samarel et al., 1987). 




(n = 15) (n = 16) 
Total RNA 
(mg/g LV wet weight) 
Total DNA 
(mg/g LV wet weight) 
Total protein 
(mg/g LV wet weight) 
Total protein/Total DNA 
mdmg) 
Total RNA/Total DNA 
(mglmd 
1.75 f 0.22 2.17 + 0.29* 1.76 f 0.19 1.74 + 0.35 
1.73 +_ 0.38 1.81 +_ 0.20 1.52 +_ 0.40 1.61 +_ 0.25 
164f 9 172 + 10 157 + 11t 164 + 14 
100 + 24 96 + 9 113 + 38 104 * 20 
1.05 f 0.18 1.22 f 0.19 1.29 + 0.62 1.09 f 0.23 
Nucleic acid and mixed cardiac protein concentration obtained from experimental animals given 
intravenous thyroxine (200 pg/kg/day) for 9 days. Thyroxine was stopped, and regression allowed to occur 
for 0,5, and 10 days (R-O, R-5), and R-10, respectively). Animals not receiving thyroxine served as controls 
(C-O). Values are mean + s.D.; n, number of experimental animals in each group. P values obtained by 
ANOVA followed by Student-Newman-Kuels test comparing data for each experimental group. P > 0.05 
unless otherwise specified. 
*P<o.o5vs. C-O. 
tP < 0.05 vs. R-O. 
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FIGURE 3. Comparison of left ventricular total car- 
diac protein (LV TCP) content vs. time. Data presented 
are weighted regression lines best describing LV TCP 
content vs. time for control (control), thyroxine treated 
(thyrotoxic), and regression (regression) animals. Control 
animals did not receive thyroxine and represent the TCP 
content of normally growing juvenile animals. Thyroxine 
treated animals received intravenous thyroxine (200 
pg/kg/d) . Regression animals received intravenous thy- 
roxine (200 pg/kg/d) for 9 days and thyroxine was 
stopped. Following cessation of hormone administration, 
both normal and thyroxine-induced growth was suppres- 
sed such that LV TCP content eventually returned to 
control levels. Values for control and thyroxine treated 
animals were previously published by Parmacek et al. 
( 1986) from this laboratory. 
Of note, no differences could be demonstrated 
between the cardiac growth characteristics of 
animals used in previous experiments of 
thyroxine-induced left ventricular hyper- 
trophy (Parmacek et al., 1986) and the control 
and thyroxine treated animals used in the 
present study. In a similar fashion, data for the 
58 animals in the regression groups were 
plotted as mean LV TCP content 
(mg/ventricle) vs. days of regression. Sequen- 
tial polynomial curve fitting and statistical 
analysis indicated that a straight line best fit 
the data for LV TCP content vs. time. 
Thus, the TCP R, for control and thyro- 
toxic rabbits were 8.1 and 15.9 mg/day, 
respectively (Table 5). Five days following 
cessation of hormone administration, the TCP 
R, decreased to 0.6 mg protein/day. Based on 
this analysis, TCP R, was reduced to less than 
10% of the value observed for normally grow- 
ing control animals (i.e. 8.1 mg/day). We 
conclude that this marked reduction in the 
TCP R, is consistent with regression of LV 
hypertrophy despite a continued (albeit negli- 
gible) accumulation of protein following cess- 
ation of hormone administration. These 
values were subsequently used to calculate the 
instantaneous fractional rate of LV TCP ac- 
cumulation (K,) in the C-O, R-O, R-5, and 
R-10 animals used in protein synthesis experi- 
ments (Table 5). These calculations indicate 
that administration of thyroxine for 9 days 
resulted in a significant increase in TCP X, 
when compared to controls. Upon discontinu- 
ation of thyroxine a marked suppression of 
TCP Ks values below both C-6 and R-O levels 
were observed in the R-5 and R-10 animals. 
VII. Alterations in LVgrotein synthesis and 
degradation during administration and withdrawal 
of thyroxine 
Data depicting alterations in LV TCP turn- 
over during administration and withdrawal of 
thyroxine are also depicted in Table 5. In- 
creased rates of both LV TCP R, and TCP Rd 
were evident after 9 days of thyroxine admini- 
stration. The accelerated accumulation of LV 
TCP in R-O animals was due to the greater 
increase in the rate of TCP R, compared to 
TCP Rd. Cessation of thyroxine administra- 
tion resulted in a return of the TCP R, to that 
observed in C-O animals, whereas the TCP Rd 
remained elevated. Thus, return of the synthe- 
tic rate to C-O levels in conjunction with the 
persistently elevated degradative rate resulted 
in a negligible rate of TCP accumulation (i.e. 
a cessation of both hormone-induced and 
normal growth). 
After 9 days of thyroxine administration, 
the efficiency of protein synthesis, expressed as 
mg TCP synthesized/day/mg RNA, was not 
significantly different ’ from C-O animals 
(Table 5). Synthetic efficiency remained un- 
changed following cessation of hormone 
administration. 
Data were also analyzed in terms of frac- 
tional rates of protein synthesis (X,) and de- 
gradation (Xd). Following administration of 
thyroxine for 9 days the TCP K, values were 
significantly elevated as compared to C-O 
animals. Discontinuation of thyroxine resulted 
in a return of TCP K, values to that observed 
in GO animals. In contrast, TCP & was not 
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TABLE 5. Left ventricular protein synthesis and degradation during regression of thyroxide-induced 
hypertrophy 
(n(z) 
A. Protein Synthesized and Degraded per day: 




(n = 8) (n = 8) 
64.1 + 15.3* 44.3 + 5.5 45.9 + 10.7 
TCP accumulation rate 
(4, w/d) 
TCP degradative rate 
(Rd, w/d) 
+ 8.1 f  15.9 + 0.6 + 0.6 
29.8 f  8.9 48.2 + 15.3* 43.7 * 5.5* 45.3 f 10.7” 
Efficiency of Protein Synthesis 
(mg protein/day/mg RNA) 





8.3 k 1.9 9.2 rt 1.8 8.2 & 1.4 7.6 +_ 1.9 
8.9 + 2.0 11.5 + 2.0* 8.1 4 1.1 8.2 + 1.8 
1.9 + 0.15 2.9 + 0.37* 0.1 + 0.01*t 0.1 I O.Ol”T 
TCP & 
(%/day) 
7.0 +_ 2.0 8.6 * 2.0 8.0 f 1.1 8.1 &- 1.8 
Experimental animals were given intravenous thyroxine (200 pg/kg/d) for 9 days. Thyroxine was stopped and 
regression allowed to occur for 0,5, and 10 days (R-O, R-5, and R-10, respectively). Animals not receiving thyroxine 
served as controls (C-O). 4, Rs and Ra are the absolute rates of left ventricular protein synthesis, accumulation, and 
degradation, respectively. K., Ic,, Kd are the fractional rates of left ventricular protein synthesis, accumulation, and 
degradation, respectively. Values are mean + s.D.; n, number of animals in each experimental group. P values obtained 
by ANOVA followed by Student-Newman-Keuls test comparing data for each experimental group. 
*P co.05 vs GO. 
tP< 0.05 vs R-9. 
significantly different after 9 days of thyroxine 
administration and remained at C-O levels 
following cessation of hormone administr- 
ation. We interpret these results as indicating 
that removal of the stimulus for thyroxine- 
induced cardiac hypertrophy was not as- 
sociated with an increased susceptibility of 
mixed cardiac proteins to proteolysis. Thus, 
regression of thyroxine-induced hypertrophy 
was not accompanied by a significant reduc- 
tion in the average half-life of mixed cardiac 
proteins. 
Discussion 
The administration of thyroxine in the rabbit 
produces cardiac hypertrophy in viuo by in- 
creasing protein synthetic rates to a greater 
degree than degradative rates, resulting in the 
net accumulation of cardiac protein (Par- 
macek et al., 1986). As demonstrated in this 
report, the cessation of thyroxine administra- 
tion results in regression of LV hypertrophy by 
returning rates of protein synthesis to control 
values while an increased amount of protein is 
degraded. 
Following discontinuation of thyroxine ad- 
ministration, we observed a significant in- 
crease in terminal body weight as well as a 
return of heart weight to body weight ratio 
towards control values. A similar rapid in- 
crease in body weight has been previously 
demonstrated in juvenile rats following cess- 
ation of thyroxine administration (Sanford et 
al., 1978). However, this increase in body 
weight was not sufficient to return terminal 
body weight or the heart weight to body 
weight ratio to that expected for age matched, 
untreated controls. During the same period, 
we demonstrated that thyroxine administra- 
tion produced a significant increase in the 
plasma concentrations of both total and free 
thyroxine. Following cessation of hormone 
administration, there was a dramatic, albeit 
transient, fall in total and free thyroxine con- 
centrations which returned to control values 
by day 10. A similar suppression of thyroxine 
levels following cessation of hormone admini- 
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stration has been previously demonstrated in 
humans receiving exogenous thyroid hormone 
(Vagenakis et al., 1975). Thus, despite the low 
concentrations of free and total thyroxine fol- 
lowing the cessation of hormone administra- 
tion, there was an accelerated increase in body 
weight, suggesting that this weight gain occur- 
red independent of plasma thyroxine 
concentrations. 
The methods employed to estimate frac- 
tional rates of protein synthesis and degrad- 
ation are based on the assumption that during 
constant intravenous infusion of E3H]leucine 
there is rapid and complete equilibration be- 
tween leucyl-tRNA and plasma leucine. We 
have previously demonstrated in both un- 
treated rabbits and rabbits treated with thy- 
roxine for 3 days that plasma leucine specific 
radioactivity and cardiac leucyl-tRNA speci- 
fic radioactivity are nearly identical following 
a constant infusion of [3H]leucine (Parmacek 
et al., 1986). Thus, plasma leucine specific 
radioactivity accurately reflects the cardiac 
leucyl-tRNA pool and is acceptable for use in 
the calculation of fractional protein synthetic 
rates for both thyroxine-treated and untreated 
control animals. However, it is possible that 
during regression of thyroxine-induced car- 
diac hypertrophy this relationship is altered, 
leading to a systematic underestimation of 
total protein fractional synthetic rates. 
Our results support the findings of previous 
investigators regarding the effect of thyroxine 
administration on protein synthesis during the 
development of cardiac hypertropty (Bonnin 
et al., 1983; Carter et al., 1982; Parmacek et al., 
1986; Crie et al., 1983). We demonstrated a 
70% increase in the TCP R, and a 62% 
increase in the TCP Rd following thyroxine 
administration; values similar to those previ- 
ously reported by this laboratory (Parmacek et 
al., 1986). Our present data also indicate that, 
in addition to increasing rates of protein turn- 
over, thyroxine administration resulted in 
hemodynamic alterations that increased car- 
diac work. The temporal relationship between 
increased cardiac work, augmented rates of 
protein synthesis, and the development of car- 
diac hypertrophy strongly supports recent ob- 
servations regarding the relative importance 
of thyroxine mediated changes in cardiac 
work vs. the direct effects of thyroxine on 
nyocardial protein metabolism (Klein, 1988; 
Klein et al., 1986; Koreckey et al., 1987). Thus, 
our results suggest that thyroxine-mediated 
alterations in cardiac work play a significant 
role in modulating rates of protein synthesis 
required for the development of cardiac 
hypertrophy. 
Following cessation of thyroxine adminis- 
tration, we demonstrated: (a) reduced TCP 
synthetic rates (R,); (b) the return of indices of 
cardiac work to control levels, and (c) the 
cessation of both normal and hormone- 
induced growth. We defined regression as a 
return of LV TCP mass towards that of age- 
matched controls. Since juvenile animals were 
used throughout the study period, cardiac 
mass was continually increasing in the control 
population due to physiologic growth. Thus, 
regression may have resulted from one of two 
mechanisms: (a) an absolute decrease in LV 
TCP mass or (b) a decreased TCP R, com- 
pared to normally growing control animals. 
Our data support the latter mechanism and 
show that LV TCP mass did not change upon 
cessation of hormone administration, but 
eventually reached a value equal to that of the 
control group. Thus, regression of thyroxine- 
induced cardiac hypertrophy was mediated, 
in part, by a return of the increased TCP R, 
back to normal. These results in the rabbit 
differ somewhat from observations of 
thyroxine-induced cardiac hypertrophy in 
rats. Previous investigators using rats have 
shown an absolute decrease in both heart 
weight (Sanford et al., 1978; Campbell and 
Gerdes, 1988) and cardiomyocyte volume 
(Campbell and Gerdes, 1988) following cess- 
ation of thyroxine administration. These ob- 
servations may reflect age, sex, and/or species 
differences between the experimental models. 
Changes in protein synthetic rates can re- 
sult from either altered protein synthetic effici- 
ency and/or capacity (Morgan et al., 1987). 
We previously demonstrated that LV protein 
synthetic efficiency was augmented after 3 
days of thyroxine administration, but re- 
turned to control levels by day 9 of hormone 
treatment. Conversely, the capacity for pro- 
tein synthesis was unchanged after 3 days of 
hormone administration, but was significantly 
increased by the second week of thyroxine 
treatment (Parmacek et al., 1986). Similar 
alterations in cardiac protein synthetic efici- 
ency and capacity in vivo have been demon- 
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strated during the development of right ven- 
tricular hypertrophy due to pulmonary artery 
banding (Nagai et al., 1988). In contrast, Siehl 
et al., (1985) demonstrated no change in pro- 
tein synthetic efficiency in their in vitro studies 
of thyroxine-induced rat cardiac hypertrophy. 
They reported a more modest increase in 
protein synthesis (25% above control in their 
study) following daily administration of thy- 
roxine for 4 days. However, protein synthetic 
rates were measured in both the control and 
thyroxine treated animals using an isolated, 
perfused working heart preparation under 
identical conditions of temperature, coronary 
flow, aortic perfusion pressure, and substrate 
supply. Thus, the thyroxine-induced alter- 
ations in body temperature and ventricular 
loading (which we have demonstrated to 
occur in viuo in response to thyroxine) were not 
simulated. Therefore, their contribution to 
accelerated protein synthesis and protein syn- 
thetic efficiency were not assessed in the study 
by Siehl et al. ( 1985). 
In contrast to changes demonstrated dur- 
ing the development of thyroxine-induced 
hypertrophy, regression was not associated 
with alterations in protein synthetic efficiency, 
although a reduction in capacity (as eviden- 
ced by a return of total RNA concentration to 
control values) was observed. Nevertheless, 
removal of the stimulus for hormone-induced 
growth affected both total protein and RNA 
turnover. Whether the reduction in RNA con- 
centration and content that accompanied re- 
gression was the result of decreased synthesis, 
or increased degradation of myocyte 
ribosomal RNA requires additional 
investigation. 
We did not demonstrate a change in the 
total DNA concentration or total protein to 
DNA ratio during the development or re- 
gression of thyroxine-induced left ventricular 
hypertrophy. These data indicate that, in the 
absence of polyploidy, some degree of hyper- 
plasia occurred. Similar results were noted by 
Parmacek et al. (1986) who found no change 
in the total DNA concentration following 9 
days of thyroxine administration. While car- 
diac myocytes lose their mitotic capacity 
shortly afterbirth, the interstitial and vascular 
cell populations retain their ability to djvide. 
The tissue homogenates used to measure total 
protein and nucleic acid content sampled all 
the varicus cardiac cell populations. Thus, the 
failure to demonstrate a cha.nge in total DNA 
concentration or total proteir to DNA ratio 
probably reflects the hyperplastic response of 
the non-myocyte cell populations to 
thyroxine-induced growth. 
The results from this report indicate that 
protein degradation played a relatively pass- 
ive role in the regulation of cardiac protein 
mass following administration and witb- 
drawal of thyroxine. The intracellular mech- 
anisms responsible for accelerated protein de- 
gradation. during the development and re- 
gression of cardiac hypertrophy are unknown. 
It is generally assumed tha.t the kinetics of 
protein degradation can best be described as a 
first-order process, in which the rate of protein 
degradation (Rd) is dependent upon the 
amount ol’protein present, and the magnitude 
of a first-order rate constant, i.e. the fractional 
rate of degradation (Kd) characterizing the 
susceptibility of proteins to degrada.tion 
(Waterlow et al., 1978). In our previous report 
(Parmacek et al., 1.986), we showed that TCP 
Kd wa.s transiently elevated during the develop- 
ment of thyroxine-induced ca.rdiac hyper- 
trophy, but by the 9th da.y of hormone a.d- 
ministration TCP & values were similar to 
that observed in control rabbits. In the pre- 
sent study, we demonstrated that TCP Kd 
values remain unchanged following hormone 
withdrawal. These results suggest that re- 
gression of thyroxine-induced hypertrophy 
was not associated with an increased suscepti-. 
bility of mixed cardiac proteins to proteolysis. 
Thus, the Rd remained elevated during the 
regression period, not because of an increased 
fraction of susceptible proteins, but because of 
an expanded total protein pool size. It must be 
recognized, however, that these Kd values are 
representative of and describe the kinetic 
behavior of a mixture of all cardiac proteins. 
It is conceivable that the susceptibility to 
proteolysis of individual proteins (including 
myofibrillar proteins) may differ during re- 
gression. Further studies are needed to evalu- 
ate the susceptibility of individual myofibrillar 
proteins to proteolysis (i.e. Kd values) during 
both the development and regression of 
thyroxine-induced cardiac hypertrophy. 
Finally, although this report provides 
evidence to indicate that accelerated rates of 
protein degradation are at least partly respon- 
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sible for the regression of cardiac protein mass 
following cessation of thyroxine, the subcel- 
lular sites and mechanisms responsible for the 
regulation of contractile protein turnover are 
unknown. Based upon this kinetic analysis it 
.>ppears that regression from hypertrophy in 
Juvenile animals is largely the result of changes 
in protein synthetic rates. The accelerated 
rates of protein degradation noted during the 
regression phase reflect the increased mass of 
the hypertrophied ventricle. 
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